The AltTox Forum is an internet-based message board that can be used to post news, announcements, information, and perspectives, as well as to encourage feedback and commentary. The scope of the Forum is the same as for AltTox.org in general: scientific and policy information related to non-animal methods for toxicity testing.
The Forum is a communications platform that provides an opportunity for stakeholders in industry, government, academia, and nongovernmental organizations to establish an online community to exchange information and discuss challenges and opportunities to advancing non-animal methods for toxicity testing. The AltTox Management Team envisions the Forum as a driving force for positive change.
Everyone visiting AltTox.org is welcome to browse and read Forum messages. However, registration is required prior to posting a message to the Forum. Anonymous postings are not allowed, and messages beyond the scope of AltTox or otherwise inappropriate will be removed. Posting messages is straightforward, but an AltTox Forum Tutorial is available for guidance. Please also see the Forum User Agreement for further information.
The Forum is moderated by experts in the field of non-animal methods of toxicity testing. The Forum Moderators monitor postings as well as initiate and participate in message threads.
- Horst Spielmann, M.D. (Free University Berlin, Germany)
- Grace Patlewicz, Ph.D. (DuPont Haskell Global Centers for Health and Environmental Sciences, United States)
- Martin Stephens, Ph.D. (Johns Hopkins Center for Alternatives to Animal Testing)
- Hajime Kojima, Ph.D. (Japanese Center for the Validation of Alternative Methods, Japan)
The scope of the Forum includes past, present, and possible future activities relevant to the development, validation, peer review, regulatory acceptance, implementation, and/or international harmonization of non-animal methods for assessing the toxic effects of substances; the general application of various non-animal technologies to toxicity testing; relevant legislation (e.g., REACH; the EU Cosmetics Directive); stakeholder efforts to address such legislation; large-scale testing programs (e.g., endocrine disruption); sector-specific testing (e.g., pesticides); validation efforts related to these programs and sectors; government policies on animal testing and alternatives; lobbying efforts to influence such programs and policies; relevant grant and educational programs; overarching scientific, logistical, and/or policy issues that are perceived as challenges or barriers to progress; and opportunities to accelerate progress.